A phase II study assessing the benefit of cisplatin re-introduction (stop and go strategy) in patients with advanced non-squamous non-small cell lung cancer (NSCLC) : The IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer).

  • Etude concernée: IFCT-1102
  • Auteurs / Authors: Fabrice Barlesi, Judith Raimbourg, Pascal Do, Patrick Dumont, Jacques Cadranel, Didier Debieuvre, Werner Hilgers, Pierre Jean Souquet, Olivier Molinier, Elisabeth A. Quoix, Alexandra Langlais, Marie Paule Lebitasy, Franck Morin, Gerard Zalcman, Jaafar Bennouna
  • Journal / Conference: ASCO
  • Année / Year: 2016
  • PMID: Poster
  • Lien vers la publication: https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.9077